|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0675 AUD | -0.74% |
|
-2.17% | -20.59% |
Executive Committee: Neurizon Therapeutics Limited
| Manager | Positions heldSince | ||
|---|---|---|---|
![John Clark](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>) John Clark |
| ||
Stefan Ross |
| ||
Nicky Wallis |
| ||
Kathryn Williams |
| ||
Daniel O'Connell |
|
Composition of the Board of Directors: Neurizon Therapeutics Limited
| Director | CommitteesSince | ||
|---|---|---|---|
Sergio Duchini |
| ||
Kathryn MacFarlane 60 year |
| ||
Ross Murdoch |
| ||
Michael Thurn |
| ||
Marcus Hughes |
|
Latest Appointments: Neurizon Therapeutics Limited
Former Officers and Directors: Neurizon Therapeutics Limited
| Insider | Positions held SinceUntil | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
| |||||||||||||||
|
|
Age distribution of managers
Parity Men Women
| Male | 9 |
|---|---|
| Female | 1 |
Of which Executive Committee
| Male | 4 |
|---|---|
| Female | 1 |
Of which Directors
| Male | 5 |
|---|---|
| Female | 0 |
Departures of Key Persons
Chairman
09/05/2024 17/05/2024
Chief Executive Officer
25/05/2018 01/09/2023
Chief Executive Officer
01/09/2023 23/04/2024
Chief Executive Officer
07/03/2017 25/05/2018
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition